Trial Profile
A Randomized, Open-label,2-Period Crossover Study to Investigate the Bioequivalence of Ertugliflozin/Sitagliptin FDC (5 mg/100 mg) and co-administration of the individual components in healthy subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2017
Price :
$35
*
At a glance
- Drugs Ertugliflozin/sitagliptin (Primary) ; Ertugliflozin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- 05 Apr 2017 New trial record
- 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics